Viatris(US:VTRS) Prnewswireยท2025-08-05 10:55Core Viewpoint - Viatris Inc. has appointed David Simmons to its Board of Directors, bringing extensive pharmaceutical industry experience and executive expertise to the company [1][4]. Group 1: Appointment Details - David Simmons has a strong background in the pharmaceutical industry, previously serving as CEO of Caliber Holdings Corporation and Chairman and CEO of PPD, Inc., where he led a workforce of over 30,000 employees and significantly increased the company's enterprise value [1][2]. - Under Simmons' leadership, PPD's total enterprise value tripled, and he oversaw its IPO in 2020 and subsequent sale to Thermo Fisher Scientific for $17.4 billion in 2021 [1][2]. Group 2: Previous Experience - Simmons has over 15 years of experience at Pfizer, where he became the first President and General Manager of the Established Products Unit, managing around 20,000 employees and 30% of Pfizer's global sales [2][3]. - He currently serves on the board of directors of Cordis and has held board positions at several other companies, including Curia Global, Launch Therapeutics, Medline Industries, and Owens & Minor [3]. Group 3: Strategic Importance - The Chair of Viatris' Board, Melina Higgins, emphasized that Simmons' background in the pharmaceutical industry and his familiarity with Viatris' established products portfolio make him a valuable addition to the Board [4]. - CEO Scott A. Smith expressed confidence that Simmons will contribute significantly to the Board's efforts in business execution and advancing the company's pipeline [4]. Group 4: Company Overview - Viatris Inc. is a global healthcare company that aims to bridge the gap between generics and brand-name products, providing access to high-quality medicines for approximately 1 billion patients annually [5]. - The company is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad, India, and focuses on addressing various healthcare needs across different life stages [5].